quizartinib 17.7 MG Oral Tablet [Vanflyta]
- RxCUI
- 2643060
- RxNorm name
- quizartinib 17.7 MG Oral Tablet [Vanflyta]
- Display name
- quizartinib 17.7 MG Oral Tablet [Vanflyta]
- Full name
- quizartinib 17.7 MG Oral Tablet [Vanflyta]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:51
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VANFLYTA | QUIZARTINIB | Daiichi Sankyo Inc. | 29cdbcfe-497d-4e78-bb7b-2d4acafe8e86 | 2026-04-16 | Boxed warning, Warnings, Adverse reactions | 2643060 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 29cdbcfe-497d-4e78-bb7b-2d4acafe8e86 | VANFLYTA 17.7 MG Oral Tablet [PSN] · quizartinib 17.7 MG Oral Tablet [Vanflyta] [SBD] · Vanflyta 17.7 MG (equivalent to 20 MG quizartinib dihydrochloride) Oral Tablet [SY] · Vanflyta 17.7 MG Oral Tablet [SY] | 4 | 11 | These highlights do not include all the information needed to use VANFLYTA safely and effectively. See full prescribing information for VANFLYTA. VANFLYTA ® (quizartinib) tablets, for oral use Initial U.S. Approval: 2023 | 20260416 |